Announced details
Adult T-cell leukemia/lymphoma (ATL)
Collaborative research related to MALT1. The research was conducted with support from AMED's Industry-Academia Collaborative Medical Innovation Creation Program (ACT-M).
Professor Seiji Ogawa (小川誠司) of the Kyoto University Graduate School of Medicine is the principal investigator. AMED is a public agency that supported this collaborative research. Details of the other counterparties are not disclosed.
Fujisawa, Kanagawa Prefecture (the company's head office)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
iScience, an international academic journal published by Cell Press; paper titled “The requirement of MALT1 activity for the growth of adult T cell leukemia/lymphoma”
| Item | Details |
|---|---|
| Names of Products / Services Covered | MALT1 inhibitor ocipumaltib (CTX-177) |
| Counterparty | Miyazaki University, Kyoto University, National Cancer Center, Japan Agency for Medical Research and Development (AMED) |
| Counterparty overview | Professor Seiji Ogawa (小川誠司) of the Kyoto University Graduate School of Medicine is the principal investigator. AMED is a public agency that supported this collaborative research. Details of the other counterparties are not disclosed. |
| Relationship with the Company | Collaborative research related to MALT1. The research was conducted with support from AMED's Industry-Academia Collaborative Medical Innovation Creation Program (ACT-M). |
| Applicable area | Adult T-cell leukemia/lymphoma (ATL) |
| Location | Fujisawa, Kanagawa Prefecture (the company's head office) |
| Source | iScience, an international academic journal published by Cell Press; paper titled “The requirement of MALT1 activity for the growth of adult T cell leukemia/lymphoma” |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The collaborative research findings were published on 23 July 2026 in iScience, an international academic journal published by Cell Press. The findings are also considered to contribute to further advances in the research and development of MALT1 inhibitors.